Breaking News Instant updates and real-time market news.

RDUS

Radius Health

$37.57

0.8 (2.18%)

10:06
10/13/17
10/13
10:06
10/13/17
10:06

Rumor: Radius Health moves up on renewed takeover chatter

  • 02

    Nov

RDUS Radius Health
$37.57

0.8 (2.18%)

05/22/17
ADAM
05/22/17
NO CHANGE
Target $85
ADAM
Buy
CV events 'may kill' Amgen's romosozumab development, says Canaccord
Canaccord analyst John Newman said Amgen (AMGN) and partner UCB's report of a higher rate of cardiovascular Serious Adverse Events for romosozumab in the Phase 3 ARCH study in osteoporosis suggests a much lower chance of FDA approval for the drug and may "kill" romosozumab's development. He notes that Merck's (MRK) cathepsin-K inhibitor was previously discontinued due to increased risk of atrial fibrillation and stroke. In addition to the safety signals, Newman points out that romosozumab was worse than Radius' (RDUS) Tymlos for non-vertebral fracture and for vertebral fracture, suggesting Radius' drug also has much better efficacy, said the analyst, who keeps a Buy rating and $85 price target on Radius Health shares, which are up $4.47, or 12.8%, to $39.40 in pre-market trading.
05/22/17
LEER
05/22/17
NO CHANGE
Target $159
LEER
Market Perform
Leerink sees only 50/50 chance of Amgen's Evenity hitting market
After Amgen (AMGN) and UCB reported an "imbalance of positively adjudicated serious cardiovascular adverse events" in its Phase 3 study of Evenity, Leerink analyst Geoffrey Porges believes the product now has only a 50/50 probability of coming to market at all. The analyst lowered his price target for Amgen shares to $159 from $160 and keeps a Market Perform rating on the name. Radius Health (RDUS), which has a drug that would compete with Evenity, is trading up 16% to $40.58 in the premarket.
05/22/17
JPMS
05/22/17
NO CHANGE
Target $74
JPMS
Overweight
Amgen data a 'clear positive' for Radius Health, says JPMorgan
JPMorgan analyst Jessica Fye believes the imbalance in observed cardiovascular serious adverse events reported by Amgen (AMGN) and UCB over the weekend for Evenity is a "clear positive" for Radius Health (RDUS). The FDA will now add results from the Phase 3 ARCH study to the regulatory review, and as a result Amgen does not expect U.S. approval for Evenity in 2017, Fye tells investors in a research note. The update is a "clear positive" for Radius Health, who has Tymlos already approved with a clean clinical safety profile, the analyst contends. She continues to believe Tymlos is well positioned for a successful launch into the large market opportunity of postmenopausal women with osteoporosis at high risk of fracture. Fye has an Overweight rating on Radius with a $74 price target. The stock in premarket trading is up 13%, or $4.62, to $39.55.
05/02/17
COWN
05/02/17
DOWNGRADE
COWN
Market Perform
Radius Health downgraded to Market Perform from Outperform at Cowen
Cowen analyst Chris Shibutani downgraded Radius Health to Market Perform due to fewer near-term drivers following a proprietary expert survey regarding the outlook for Tymlos. The analyst said Tymolos has attractive features versus Forteo but differentiation is relatively limited and physicians expressed concerns over pricing and reimbursement. Further, Amgen's romosozumab's potential approval near-term and the potential entry of Forteo generic/biosimilar long-term are potential competitive threats.

TODAY'S FREE FLY STORIES

XEC

Cimarex Energy

$115.32

0.29 (0.25%)

04:55
10/20/17
10/20
04:55
10/20/17
04:55
Conference/Events
Cimarex Energy management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 08

    Nov

04:55
10/20/17
10/20
04:55
10/20/17
04:55
General news
Breaking General news story  »

Federal Reserve Chair…

04:55
10/20/17
10/20
04:55
10/20/17
04:55
General news
Breaking General news story  »

Federal Reserve Chair…

04:55
10/20/17
10/20
04:55
10/20/17
04:55
General news
Existing Home Sales to be reported at 10:00 »

September Existing Home…

CPST

Capstone Turbine

$1.09

0.01 (0.93%)

04:55
10/20/17
10/20
04:55
10/20/17
04:55
Conference/Events
Capstone Turbine management to meet with Oppenheimer »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 24

    Oct

  • 25

    Oct

  • 26

    Oct

MRK

Merck

$63.75

0.24 (0.38%)

, GSK

GlaxoSmithKline

$41.10

0.09 (0.22%)

04:55
10/20/17
10/20
04:55
10/20/17
04:55
Conference/Events
European Society of Gene & Cell Therapy will hold a conference »

25th Anniversary Congress…

MRK

Merck

$63.75

0.24 (0.38%)

GSK

GlaxoSmithKline

$41.10

0.09 (0.22%)

TECH

Bio-Techne

$123.46

0.33 (0.27%)

PLL

Pall Corp.

ICEL

Cellular Dynamics

ABEO

Abeona Therapeutics

$17.75

0.25 (1.43%)

KITE

Acquired by GILD 9/17

PFE

Pfizer

$36.24

0.41 (1.14%)

BMRN

BioMarin

$88.13

-0.49 (-0.55%)

SHPG

Shire

$147.82

1.53 (1.05%)

TIG

TiGenix

$24.21

0.91 (3.91%)

BIIB

Biogen

$342.42

-2.16 (-0.63%)

QURE

uniQure

$15.16

5.69 (60.08%)

SGMO

Sangamo

$13.95

-0.2 (-1.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 20

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 26

    Oct

  • 27

    Oct

  • 31

    Oct

  • 31

    Oct

  • 06

    Nov

  • 07

    Nov

  • 08

    Nov

  • 16

    Nov

  • 29

    Nov

  • 30

    Nov

  • 02

    Feb

  • 28

    Feb

  • 17

    Oct

LXRX

Lexicon

$11.34

0.15 (1.34%)

04:55
10/20/17
10/20
04:55
10/20/17
04:55
Conference/Events
Lexicon has a conference call hosted by JPMorgan »

JPMorgan Analyst Fye will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

ADBE

Adobe

$171.73

18.73 (12.24%)

04:55
10/20/17
10/20
04:55
10/20/17
04:55
Conference/Events
Adobe to hold a conference »

Adobe Max: The Creativity…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 06

    Nov

TGEN

Tecogen

$2.95

-0.0371 (-1.24%)

04:55
10/20/17
10/20
04:55
10/20/17
04:55
Conference/Events
Tecogen management to meet with Maxim »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

BOLD

Audentes Therapeutics

$25.05

-0.36 (-1.42%)

04:55
10/20/17
10/20
04:55
10/20/17
04:55
Conference/Events
William Blair biotech analyst holds an analyst/industry conference call »

Biotech Analyst Prasad,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 20

    Oct

04:55
10/20/17
10/20
04:55
10/20/17
04:55
General news
Breaking General news story  »

Cleveland Federal Reserve…

GME

GameStop

04:55
10/20/17
10/20
04:55
10/20/17
04:55
Conference/Events
GameStop management to meet with Loop Capital »

Field trip to company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

VSTM

Verastem

$3.95

0.05 (1.28%)

04:55
10/20/17
10/20
04:55
10/20/17
04:55
Conference/Events
Verastem management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

04:55
10/20/17
10/20
04:55
10/20/17
04:55
General news
Breaking General news story  »

Week of 10/20…

REGN

Regeneron

$440.94

1.57 (0.36%)

04:50
10/20/17
10/20
04:50
10/20/17
04:50
Downgrade
Regeneron rating change  »

Regeneron downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

03:45
10/20/17
10/20
03:45
10/20/17
03:45
General news
FX Action: USD-CAD has rallied back above 1.2500 »

FX Action: USD-CAD has…

02:55
10/20/17
10/20
02:55
10/20/17
02:55
General news
FX Update: The dollar has rallied across the board »

FX Update: The dollar…

01:45
10/20/17
10/20
01:45
10/20/17
01:45
General news
Breaking General news story  »

Federal Reserve Chair…

STLD

Steel Dynamics

$37.78

1.34 (3.68%)

21:35
10/19/17
10/19
21:35
10/19/17
21:35
Upgrade
Steel Dynamics rating change at KeyBanc »

Steel Dynamics upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

RXDX

Ignyta

$16.65

0.4 (2.46%)

20:30
10/19/17
10/19
20:30
10/19/17
20:30
Syndicate
Ignyta 10M share Secondary priced at $16.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

  • 20

    Oct

PG

Procter & Gamble

$91.59

-0.4904 (-0.53%)

, GE

General Electric

$23.58

0.46 (1.99%)

20:25
10/19/17
10/19
20:25
10/19/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

PG

Procter & Gamble

$91.59

-0.4904 (-0.53%)

GE

General Electric

$23.58

0.46 (1.99%)

HON

Honeywell

$143.62

0.18 (0.13%)

SLB

Schlumberger

$64.50

-1.41 (-2.14%)

STI

SunTrust

$59.11

-0.18 (-0.30%)

SYF

Synchrony

$31.71

0.2 (0.63%)

CFG

Citizens Financial

$37.43

0.25 (0.67%)

KSU

Kansas City Southern

$103.78

0.97 (0.94%)

GNTX

Gentex

$20.66

0.2 (0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 22

    Oct

  • 02

    Nov

WILC

G. Willi-Food

$5.85

-0.14 (-2.34%)

18:35
10/19/17
10/19
18:35
10/19/17
18:35
Hot Stocks
G. Willi-Food receives notice from Arla Food ending distribution agreement »

G. Willi-Food's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MIC

Macquarie Infrastructure

$71.26

-0.46 (-0.64%)

18:30
10/19/17
10/19
18:30
10/19/17
18:30
Hot Stocks
Macquarie Infrastructure CEO to become CEO of Macquarie Atlas Roads in 2018 »

Macquarie Infrastructure…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

BIDU

Baidu

$264.52

-4.45 (-1.65%)

18:30
10/19/17
10/19
18:30
10/19/17
18:30
Hot Stocks
Baidu collaborating with China's BAIC Group and King Long for autonomous driving »

Baidu signed strategic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

IBKC

Iberiabank

$80.15

0.05 (0.06%)

18:27
10/19/17
10/19
18:27
10/19/17
18:27
Hot Stocks
IBERIABANK to acquire Gibraltar Private Bank & Trust »

IBERIABANK Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 15

    Nov

  • 28

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.